Predictors of no-reflow phenomenon in patients with type 2 diabetes mellitus undergoing elective percutaneous coronary intervention: the emerging role of the triglyceride–glucose index
References
- Figulla HR, Lauten A, Maier LS, Sechtem U, Silber S, Thiele H. Percutaneous coronary intervention in stable coronary heart disease -is less more? Dtsch Arztebl Int. 2020;117(9):137–44. doi:10.3238/arztebl.2020.0137.
- Khan SQ, Ludman PF. Percutaneous coronary intervention. Medicine. 2022;50(7):437–44. doi:10.1016/j.mpmed.2022.04.008.
- Annibali G, Scrocca I, Aranzulla TC, Meliga E, Maiellaro F, Musumeci G. “No-reflow” phenomenon: a contemporary review. J Clin Med. 2022;11(8):2233. doi:10.3390/jcm11082233.
- Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: state of the art. Arch Cardiovasc Dis. 2015;108(12):661–74. doi:10.1016/j.acvd.2015.09.006.
- Eldamanhory AS, AbdelAziz TA, Mohamed MAA, Kandeel NT, Shehata IE. Understanding the no-reflow phenomenon in coronary interventions: a comprehensive review. ZUMJ. 2024;30:4207–15. doi:10.21608/zumj.2024.265445.3137.
- Zhao SR, Huang R, Liu F, Li Y, Gong Y, Xing J. Study on correlation between type 2 diabetes and no-reflow after PCI. Dis Markers. 2022:7319277. doi:10.1155/2022/7319277.
- Abdul Basith Khan M, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–111. doi:10.2991/jegh.k.191028.001.
- Zhou Y, Chen Y, Tang Y, Zhang S, Zhuang Z, Ni Q. Rising tide: the growing global burden and inequalities of early-onset type 2 diabetes among youths aged 15–34 years (1990–2021). Diabetol Metab Syndr. 2025;17(1):103. doi:10.1186/s13098-025-01673-0.
- Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. Health Sci Rep. 2024;7(3):e2004. doi:10.1002/hsr2.2004.
- Liu F, Huang R, Li Y, Zhao S, Gong Y, Xu Z. In-hospital peak glycemia in predicting no-reflow phenomenon in diabetic patients with STEMI treated with primary percutaneous coronary intervention. J Diabetes Res. 2021;2021:6683937. doi: 10.1155/2021/6683937.
- Ma J, Wu P, Ma S, Ma X, Jin P, Jia S. The triglyceride–glucose index is associated with no-reflow phenomenon in STEMI patients with type 2 diabetes after percutaneous coronary intervention. Front Cardiovasc Med. 2024;11:1386318. doi:10.3389/fcvm.2024.1386318.
- Altunova M, Koseoglu M. A novel marker triglyceride glucose index in predicting the development of no-reflow in acute coronary syndrome without ST-segment elevation. Med Bull Haseki. 2024;62:1–8. doi:10.4274/haseki.galenos.2024.9694.
- Jeon HS, Youn YJ, Lee TS, Kim SY, Lee SJ, Kim SE, et al. Prediction of no-reflow phenomenon in elective percutaneous coronary intervention for non-acute myocardial infarction. BMC Cardiovasc Disord. 2026;26(1):290. doi:10.1186/s12872-026-05647-6.
- Pantea-Rosan LR, Tica O, Mădălina M, Pantea V, Tica O, Cosmin Mihai V, et al. Predictors of no-reflow phenomenon: diabetes mellitus type II and obesity and their associated mortality in stemi patients after primary PCI. Intern Med. 2019;16(4):7–12. doi:10.2478/inmed-2019-0072.
- Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract. 2022;28(10):923–1049. doi:10.1016/j.eprac.2022.08.002.
- Chen Y, Peet J, Hausin N, Hinds D, Jayasinghe R, Kennedy W, et al. Developing a same-day discharge clinical pathway for patients undergoing elective percutaneous coronary intervention using a nominal group technique. Heart Lung Circ. 2026;35(1):116–26. doi:10.1016/j.hlc.2025.07.006.
- Waqar A, Ajab Khan K, Syed Muhammad H, Jalal Ud D, Hashim B, Fazal Ur R. Frequency of no-flow in patients following PCI in stable coronary artery disease. J Health Wellness Community Res. 2025;3(7):1–9. doi:10.61919/anfvw221.
- Omar M, Kang Min G, Jung Moon K, Ahn J-H, Koh J-S, Guevarra Phil I, et al. Association and prognostic implications of “no-reflow phenomenon” and hypercoagulability in patients with ST-segment elevation myocardial infarction. JACC Asia. 2025;5(11):1487–501. doi:10.1016/j.jacasi.2025.07.015.
- Elrayes M, Youssif A, Youssef M. Predictors of no-reflow phenomenon after percutaneous coronary intervention in ST-segment elevation myocardial infarction patients. ZUMJ. 2022;28(6):1205–13. doi:10.21608/zumj.2021.94220.2340.
- Qu Z, Guan X. Predictive value of the triglyceride-glucose index for no-reflow phenomenon after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction complicated by metabolic syndrome. Am J Transl Res. 2024;16(10):5539–51. doi:10.62347/hqvs4428.
- Yang J, Xu D, Liu X, Zhao Z, Zhang J. The triglyceride-glucose index and neutrophil-to-lymphocyte ratio jointly predict the no-reflow phenomenon in T2DM patients with STEMI after primary PCI. PLoS One. 2026;21(3):e0345466. doi:10.1371/journal.pone.0345466.
- Fajar JK, Heriansyah T, Rohman MS. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: a meta-analysis. Indian Heart J. 2018;70 Suppl 3(Suppl 3):S406–18. doi:10.1016/j.ihj.2018.01.032.
- Satti Z, Omari M, Bawamia B, Cartlidge T, Egred M, Farag M, et al. The use of thrombectomy during primary percutaneous coronary intervention: resurrecting an old concept in contemporary practice. J Clin Med. 2024;13(8):2291. doi:10.3390/jcm13082291.
Language: English
Published on: Sep 19, 2026
Published by: Romanian Society of Cardiology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Hala Mahfouz Badran, Mohamed Kadry Ghazy Mohamed, Ghada Mahmoud Soltan, Awny Gamal Shalaby, published by Romanian Society of Cardiology
This work is licensed under the Creative Commons Attribution 4.0 License.